A study to assess COPD symptom-based management and to optimise treatment strategy in Japan (COSMOS-J) based on GOLD 2011

International Journal of COPD

Volumn 8, Issue , 2013, Pages 453-459

  Betsuyaku, Tomoko ^a   Kato, Motokazu ^b   Fujimoto, Keisaku ^c   Hagan, Gerry ^d   Kobayashi, Akihiro ^e   Hitosugi, Hideki ^e   James, Mark ^e   Jones, Paul W ^f  

^a KEIO UNIVERSITY   (Japan)

^b Kishiwada City Hospital   (Japan)

^c SHINSHU UNIVERSITY   (Japan)

^d GlaxoSmithKline KK ^*

^e Development and Medical Affairs Division   (Japan)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

COPD; Exacerbation risk; GOLD; Symptom; TRIPLE therapy

Indexed keywords

ADOAIR; FLUTICASONE PROPIONATE PLUS SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; COPD ASSESSMENT TEST; DISEASE EXACERBATION; INHALER; JAPAN; MULTICENTER STUDY (TOPIC); PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPTOM ASSESSMENT;

COPD; EXACERBATION RISK; GOLD; SYMPTOM; TRIPLE THERAPY;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FORCED EXPIRATORY VOLUME; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LUNG; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESEARCH DESIGN; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84885039844     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S48298     Document Type: Article

References (27)

1. The Japanese Respiratory Society. Guidelines for the Diagnosis and Treatment of COPD. 3rd ed. Tokyo: Japanese Respiratory Society; 2009.
2. Lopez AD, Shibuya K, Rao C, etal. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27: 397-412.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
4. Global initiative for chronic Obstructive Lung Disease (GOLD) [homepage on the Internet]. 2010. Available from: http://www.goldcopd.org/Guidelines/guideline-2010-gold-report.html. Accessed March 25, 2013.
5. Global initiative for chronic Obstructive Lung Disease (GOLD). 2011; http://www.goldcopd.org/Guidelines/guideline-2011-gold-report.html. Accessed March 25, 2013.
6. Global initiative for chronic Obstructive Lung Disease (GOLD). 2013; http://www.goldcopd.org/Guidelines/guideline-2013-gold-report.html. Accessed March 25, 2013.
7. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648-654.
8. Jones PW, Brusselle G, Dal Negro RW, etal. Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J. 2011;38:29-35.
9. Tsuda T, Suematsu R, Kamohara K, etal. Development of the Japanese version of the COPD Assessment Test. Respir Investig. 2012;50: 34-39.
10. Ichinose M, Aizawa H, Ishizaka A, etal. [Chronic obstructive pulmonary disease (COPD) burden in Japan: confronting COPD Japan survey.] Nihon Kokyuki Gakkai Zasshi. 2007;45(12):927-935. Japanese [with English abstract].
11. Fukuchi Y, Nishimura M, Ichinose M, etal. COPD in Japan: the Nippon COPD Epidemiology study. Respirology. 2004;9:458-465.
12. Nakano Y, Nagai A, Mishima M, Yoshimoto D, Hagan G. [Investigation of COPD management in primary care in Japan using hand-held spirometer.] Kokyu. 2012;31:273-281. Japanese.
13. Aaron SD, Vandemheen KL, Fergusson D, etal; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545-555.
14. Perng DW, Wu CC, Su KC, Lee YC, Perng RP, Tao CW. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids. Respirology. 2006;11:598-602.
15. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of 'triple' therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008;63:592-598.
16. Welte T, Miravitlles M, Hernandez P, etal. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:741-750.
17. Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012;106(1): 91-101.
18. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax.1999;54:581-586.
19. GlaxoSmithKline. Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Meicine; 2012 [updated July 11, 2013]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01762800?term=NCT01762800&rank=1. NLM identifier: NCT01762800. Accessed August 28, 2013.
20. Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S; EXACT-PRO Study Group. Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diary. Am J Respir Crit Care Med. 2011;183:323-329.
21. Jones PW, Chen WH, Wilcox TK, Sethi S, Leidy NK; EXACT-PRO Study Group. Characterizing and quantifying the symptomatic features of COPD exacerbations. Chest. 2011;139(6):1388-1394.
22. Leidy NK, Wilcox TK, Jones PW, etal; EXACT-PRO Study Group. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome measure. Value Health. 2010;13:965-975.
23. Schmier JK, Halpern MT, Higashi MK, Bakst A. The quality of life impact of acute exacerbations of chronic bronchitis (AECB): a literature review. Qual Life Res. 2005;14:329-347.
24. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA. 2003;290(17):2301-2312.
25. Bahadori K, FitzGerald JM. Risk factors of hospitalization and readmission of patients with COPD exacerbation: a systematic review. Int J Chron Obstruct Pulmon Dis. 2007;2:241-251.
26. Vestbo J, Anderson JA, Calverley PM, etal. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J. 2011;5:44-49.
27. Keene ON, Vestbo J, Anderson JA, etal. Methods for therapeutic trials in COPD: lessons from the TORCH trial. Eur Respir J. 2009;34: 1018-1023.